Implantable infusion pumps market seen reaching $28.25 billion by 2030

The implantable infusion pumps market is forecast to grow from $20.32 billion in 2025 to $28.25 billion by 2030, driven by chronic disease demand, aging populations and more connected dosing technology. North America led the market in 2025, while Asia-Pacific ranked second.

Why it matters: - Implantable infusion pumps are used to deliver medication over long periods for conditions such as chronic pain, cancer-related pain, spasticity and diabetes. - The market’s growth signals rising demand for long-term, precise drug delivery systems as chronic disease treatment expands. - The forecast points to broader adoption of smart, connected and homecare-friendly infusion technologies.

What happened: - The Business Research Company published new market research on the global implantable infusion pumps market on Aug. 11, 2026. - The report values the market at $20.32 billion in 2025 and projects $21.73 billion in 2026. - The report forecasts the market will reach $28.25 billion by 2030. - The company released a free sample of the report. - The company also published the full market report.

The details: - The market is expected to grow at a 6.9% CAGR from 2025 to 2026. - The report projects a 6.8% CAGR through 2030. - Growth in the near term is tied to more chronic pain disorders, higher diabetes prevalence, more cancer treatment procedures, better pump design and expansion of specialized clinical care services. - Longer-term growth is linked to wider use of smart infusion technologies, remote patient monitoring, personalized dosing, digital therapeutics and implantable pumps in homecare settings. - Key trends identified in the report include programmable infusion pumps, long-term pain management devices, smart and connected pump systems, implantable insulin delivery options and tighter dosing precision. - Implantable infusion pumps are inserted beneath the skin and can deliver medication to the bloodstream, spinal fluid or targeted areas.

Between the lines: - The aging population is one of the strongest demand drivers because older adults are more likely to need chronic disease management. - The report defines aging population pressure through the ratio of people 65 and older to the working-age population. - Eurostat said in February 2025 that the European Union had about 449 million people in 2024, with more than 21.6% aged 65 or older. - Eurostat also reported an EU median age of 44.7 years and an old-age dependency ratio that rose from 33.4% in 2023 to 33.9% in 2024. - North America was the largest regional market in 2025. - Asia-Pacific ranked second in 2025. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel forecasting dashboards, market hotspot infographics and updated graphics.

What's next: - Market growth is expected to continue as health systems adopt more connected devices and pay more attention to remote monitoring. - Broader use in homecare and more personalized dosing could become important demand drivers through 2030. - The report points to more investment in digital therapeutics and implantable insulin delivery as areas to watch.

The bottom line: - The implantable infusion pumps market is on track for steady mid-single-digit growth, with aging populations and smarter delivery systems shaping the next phase of expansion.